Scienture Holdings, Inc.(SCNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SCNX Scienture Holdings, Inc.

Market Closed 04-10 16:00:00 EDT

0.3330

-0.0080

-2.35%

盘后0.3331

+0.0001+0.03%

19:23 EDT

High0.3700	Low0.3330	Vol437.72K
Open0.3419	D1 Closing0.3410	Amplitude10.85%
Mkt Cap13.53M	Tradable Cap11.32M	Total Shares40.63M
T/O151.36K	T/O Rate1.29%	Tradable Shares33.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SCNX","market":"US","secType":"STK","nameCN":"Scienture Holdings, Inc.","latestPrice":0.333,"timestamp":1775851200000,"preClose":0.341,"halted":0,"volume":437723,"hourTrading":{"tag":"盘后","latestPrice":0.3331,"preClose":0.333,"latestTime":"19:23 EDT","volume":24258,"amount":8331.3288,"timestamp":1775863380196,"change":0.0001,"changeRate":0.0003,"amplitude":0.081081},"delay":0,"changeRate":-0.02346041055718477,"floatShares":33992500,"shares":40630815,"eps":-2.704855,"marketStatus":"Market Closed","change":-0.008,"latestTime":"04-10 16:00:00 EDT","open":0.3419,"high":0.37,"low":0.333,"amount":151360.65200685,"amplitude":0.108504,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.704855,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":7,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":0.341,"preHourTrading":{"tag":"盘前","latestPrice":0.347,"preClose":0.341,"latestTime":"09:29 EDT","volume":8432,"amount":2922.62538544,"timestamp":1775827760016,"change":0.006,"changeRate":0.017595,"amplitude":0.05132},"postHourTrading":{"tag":"盘后","latestPrice":0.3331,"preClose":0.333,"latestTime":"19:23 EDT","volume":24258,"amount":8331.3288,"timestamp":1775863380196,"change":0.0001,"changeRate":0.0003,"amplitude":0.081081},"volumeRatio":0.874746762371064},"requestUrl":"/m/hq/s/SCNX","defaultTab":"news","newsList":[{"id":"2625797216","title":"Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2625797216","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625797216?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:05","pubTimestamp":1775477100,"startTime":"0","endTime":"0","summary":"COMMACK, NY, April  06, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/06/3268403/0/en/Scienture-Provides-Annual-Shareholder-Update-Outlining-Significant-Progress-and-Strategic-Priorities-for-the-Year-Ahead.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ARB","BK4097","PRGS","LU2065732104.USD","SCNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623464833","title":"BRIEF-Scienture Reports Year End 2025 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623464833","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623464833?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:10","pubTimestamp":1774879819,"startTime":"0","endTime":"0","summary":"BRIEF-Scienture Reports Year End 2025 Financial Results And Provides Business UpdateMarch 30 (Reuters) - Scienture Holdings Inc SCNX.O:SCIENTURE REPORTS YEAR END 2025 FINANCIAL RESULTS AND PROVIDES BU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA51DR7M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","SCNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623678317","title":"Scienture FY25 operating loss widens to $42.6 million; gross margin climbs 7,240 bps to 76.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623678317","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623678317?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:10","pubTimestamp":1774872603,"startTime":"0","endTime":"0","summary":"Scienture posted a net loss of $41.5 million for 2025, swinging from net income of $9.1 million.Gross margin widened 72.4 percentage points to 76.8%.Cash and cash equivalents climbed to about $6.7 million.Management pointed to momentum for Arbli, while targeting a commercial launch of REZENOPY in Q2 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL2r50kc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4112","SCNX","LU0314104364.USD","LU2095319765.USD","IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","SG9999014021.USD","SG9999014005.SGD","BK4167","NDAQ","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4588","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623106813","title":"SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623106813","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623106813?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:07","pubTimestamp":1774872420,"startTime":"0","endTime":"0","summary":"Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March  30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for exis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264594/0/en/SCIENTURE-Reports-Year-End-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167","ARB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623594312","title":"EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2623594312","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623594312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:46","pubTimestamp":1774871167,"startTime":"0","endTime":"0","summary":"Scienture reports 216% revenue growth in 2025, driven by Arbli uptake, patent wins, and expanded healthcare access across the US.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/03/51535239/exclusive-penny-stock-scienture-reports-revenue-surge-expanding-market-access-in-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312374","title":"Scienture FY25 Revenue $431.6K Vs $136.6K YoY; Net Loss Per Common Share $(2.70) Vs $(5.41) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312374","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312374?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:45","pubTimestamp":1774871116,"startTime":"0","endTime":"0","summary":"Scienture FY25 Revenue $431.6K Vs $136.6K YoY; Net Loss Per Common Share $(2.70) Vs $(5.41) YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51535218/scienture-fy25-revenue-431-6k-vs-136-6k-yoy-net-loss-per-common-share-2-70-vs-5-41-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622826859","title":"Scienture Holdings Inc  expected to post a loss of 28 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826859","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622826859?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:49","pubTimestamp":1774612144,"startTime":"0","endTime":"0","summary":"Scienture Holdings Inc  expected to post a loss of28cents a share - Earnings Preview Scienture Holdings Inc SCNX.OQ SCNX.O is expected to  report resultson March 30 (estimated) for the period ending D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F0U6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","SCNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620738815","title":"Scienture Holdings Inc  expected to post a loss of 28 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738815","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738815?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:19","pubTimestamp":1774005545,"startTime":"0","endTime":"0","summary":"Scienture Holdings Inc  expected to post a loss of28cents a share - Earnings Preview Scienture Holdings Inc SCNX.OQ SCNX.O is expected to  report resultson March 24 (estimated) for the period ending D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4080WA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","SCNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618928553","title":"Scienture Shares Surge 48% After Co Signs Deals to Expand Reach of Opioid Overdose Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2618928553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618928553?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:32","pubTimestamp":1773235940,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL4N3ZZ1C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCNX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618940746","title":"Why Is Scienture Holdings Stock (SCNX) Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940746?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:15","pubTimestamp":1773234915,"startTime":"0","endTime":"0","summary":"Scienture Holdings stock rallied after the company revealed new purchase order agreements.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-scienture-holdings-stock-scnx-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-scienture-holdings-stock-scnx-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","SCNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618594748","title":"Shares of Scienture up 60.1% Premarket After Co Signs Deals to Expand Reach of Opioid Overdose Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2618594748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618594748?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:52","pubTimestamp":1773233522,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL4N3ZZ191:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","SCNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618944045","title":"Scienture signs GPO agreements for REZENOPY reaching over 5,000 U.S. institutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2618944045","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618944045?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:05","pubTimestamp":1773230725,"startTime":"0","endTime":"0","summary":"Scienture said it formalized multiple Group Purchasing Organization agreements for REZENOPY  Nasal Spray 10 mg. The agreements provide access to more than 5,000 U.S. healthcare institutions, including hospitals, clinics and nursing homes. Scienture said the agreements represent potential penetration into about 60% of the U.S. institutional market. The company cited IQVIA data showing the U.S. naloxone market at USD 141 million in annual sales and 9.4 million prescription units.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL42sbzB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU0882574055.USD","BK4167","IE00BKPKM429.USD","LU0980610538.SGD","IE00B3QW5Z07.USD","LU1261432733.SGD","LU1989764748.USD","SG9999014005.SGD","LU0528227936.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU1791710582.SGD","LU0130103400.USD","LU0648000940.SGD","LU0130517989.USD","LU0314104364.USD","LU0648001328.SGD","LU1201861165.SGD","SG9999014039.USD","BK4530","LU0198837287.USD","BK4112","LU0130518102.USD","SG9999014021.USD","SG9999014013.SGD","BK4585","IE00BGHQF748.EUR","LU0477156953.USD","LU1201861249.SGD","LU1989764664.SGD","LU2095319765.USD","LU2210150020.SGD","IQV","SCNX","LU0477156797.USD","LU1791710400.SGD","LU0130102774.USD","NDAQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618594296","title":"SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2618594296","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618594296?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:05","pubTimestamp":1773230700,"startTime":"0","endTime":"0","summary":"Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers U.S. naloxone market totals $141","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/11/3253734/0/en/SCIENTURE-Broadens-Commercial-Access-for-REZENOPY-Highest-Dose-FDA-Approved-Naloxone-Nasal-Spray-Through-GPO-Agreements-Reaching-Over-5-000-U-S-Institutions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","BK4588","BK4585","SCNX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614741693","title":"Scienture Holdings Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2614741693","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614741693?lang=en_us&edition=fundamental","pubTime":"2026-02-25 01:50","pubTimestamp":1771955400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SCNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 12:50 ET (17:50 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613712681","title":"Scienture initiated with a Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712681","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613712681?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:33","pubTimestamp":1771940002,"startTime":"0","endTime":"0","summary":"Maxim initiated coverage of Scienture (SCNX) with a Buy rating and $1.50 price target Published first on TheFly – the ultimate source for real-time...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scienture-initiated-with-a-buy-at-maxim-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scienture-initiated-with-a-buy-at-maxim-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","SCNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608787246","title":"BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney","url":"https://stock-news.laohu8.com/highlight/detail?id=2608787246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608787246?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:17","pubTimestamp":1770128229,"startTime":"0","endTime":"0","summary":"** Palantir Technologies Inc PLTR.O:BUZZ - Jumps as US government contracts boost quarterly sales nL4N3YZ0PE** Merck & Co Inc MRK.N:BUZZ - Falls on downbeat 2026 profit and sales forecasts nL4N3YZ0U8     ** Newmont Corp NEM.N:     ** Gold Fields Ltd GFI.N:** AngloGold Ashanti PLC AU.N: ** Harmony Gold Mining Co Ltd HMY.N:BUZZ - Gold, silver miners gain as metal prices edge higher after two-session rout nL4N3YZ0ST** McDonald's Corp MCD.N:BUZZ - Up after brokerage BTIG upgrades to 'buy'  nL6N3YY0WK** SoFi Technologies Inc SOFI.O:BUZZ - Rises after J.P. Morgan upgrades to 'overweight' nL6N3YZ0MY     ** Rio Tinto PLC RIO.N:              ** BHP Group Ltd BHP.N:** Southern Copper Corp SCCO.N: ** Freeport-McMoRan Inc FCX.N:BUZZ - Copper miners rise on China stockpiling, stronger risk sentiment nL4N3YZ0W3** PepsiCo Inc PEP.O:BUZZ - Falls after reaffirming annual earnings forecast despite Q4 revenue beat nL4N3YZ0YH** FedEx Corp FDX.N:BUZZ - Gains after Bernstein upgrades rating to 'outperform' ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL6N3YZ0PY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLTG","MPC","DIS","AU","EVR","GTBP","MCD","PLTA","BK4559","IVVD","LU1223082196.USD","PEP","DVA","NEM","PLTY","ETN","RIO.AU","PLTU","PLTW","OVV","RIO.UK","SCNX","PTIR","PYPG","WST","SOC","PLTD","RARE","LU1066051225.USD","PLT","BHP.AU","FDX","JBLU","MRK","HPQ","PLOO","SOFX","LU1162221912.USD","PLYY","VSEC","PYPY","ADM","BALL","PLTZ"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2608879095","title":"BUZZ-Scienture jumps after expanding access to hypertension drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2608879095","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608879095?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:17","pubTimestamp":1770124624,"startTime":"0","endTime":"0","summary":"BUZZ-Scienture jumps after expanding access to hypertension drug** Shares of drugmaker Scienture Holdings SCNX.O rise 10.34% to $0.4993 premarket** Co says it has expanded access to Arbli, its ready-to-use liquid losartan for high blood pressure** Losartan treats hypertension, a condition where consistently high blood pressure increases the risk of stroke and heart disease - SCNX** Co says Arbli now available at more than 2,500 healthcare sites, with coverage for 100 million insured Americans** Expects continued Arbli prescription growth in Q1 and wider insurance and pharmacy coverage** Says its nasal spray for opioid overdose emergencies, Rezenopy, is set for a U.S. launch in Q2 2026 ** Shares fell ~92% in 2025","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL4N3YZ1A5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608791448","title":"Scienture Holdings Reaffirms Q1 2026 Growth Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2608791448","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608791448?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:05","pubTimestamp":1770123916,"startTime":"0","endTime":"0","summary":"Scienture Holdings Inc. outlined its outlook for the first quarter of 2026, expecting continued sequential growth in prescription volumes and adoption of ARBLI, its FDA-approved oral suspension of losartan potassium. The company anticipates improved commercial efficiency as initial launch investments begin generating recurring demand. Scienture also projects further expansion of payer and pharmacy engagement, which is expected to broaden patient access across both commercial and government sectors. The company reported a significant strengthening of its balance sheet in the last quarter, including a substantial reduction in outstanding debt and an increase in its cash position to approximately $7.0 million as of December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLc0zmbC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4167","LU2095319765.USD","NDAQ","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","SG9999014021.USD","SG9999014039.USD","SG9999014005.SGD","IE00BKPKM429.USD","BK4112","SCNX","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608871631","title":"SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium","url":"https://stock-news.laohu8.com/highlight/detail?id=2608871631","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608871631?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:05","pubTimestamp":1770123900,"startTime":"0","endTime":"0","summary":"Company highlights accelerating access and revenue growth for ARBLI and confirms REZENOPY launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Ou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3231048/0/en/SCIENTURE-Provides-Commercial-Update-on-ARBLI-the-First-FDA-Approved-Ready-to-Use-Oral-Suspension-of-Losartan-Potassium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARB","SCNX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603619598","title":"BUZZ-Scienture Holdings jumps after U.S. FDA clears opioid overdose spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2603619598","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603619598?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:25","pubTimestamp":1768397155,"startTime":"0","endTime":"0","summary":"BUZZ-Scienture Holdings jumps after U.S. FDA clears opioid overdose spray** Shares of specialty pharma firm Scienture Holdings SCNX.O rise 19.99% to $0.6472 premarket** Co says U.S. FDA has approved a new high-dose nasal spray, Rezenopy, for treating opioid overdoses** Says spray delivers 10mg naloxone to reverse overdoses from powerful opioids including fentanyl** Adds SCNX holds exclusive U.S. sales rights; Summit Biosciences will manufacture the product** Patent protection runs through February 2041; naloxone market worth $154 million, with 9.3 million units sold annually - IQVIA data** As of last close, stock down ~92% over the past year","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nL4N3YF19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU1791710582.SGD","LU0477156953.USD","SCNX","LU1791710400.SGD","BK4585","LU0648000940.SGD","LU0477156797.USD","LU1201861249.SGD","LU0198837287.USD","BK4530","LU1201861165.SGD","IQV","LU1989764664.SGD","BK4167","LU0130102774.USD","BK4588","LU0130517989.USD","LU1989764748.USD","LU0980610538.SGD","LU0130103400.USD","LU1261432733.SGD","LU0882574055.USD","LU0130518102.USD","LU0648001328.SGD","LU0528227936.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.scientureholdings.com","stockEarnings":[{"period":"1week","weight":0.1239},{"period":"1month","weight":-0.2825},{"period":"3month","weight":-0.4055},{"period":"6month","weight":-0.525},{"period":"1year","weight":-0.5924},{"period":"ytd","weight":-0.3471}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Lutz, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.119636},{"month":2,"riseRate":0.333333,"avgChangeRate":0.150517},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.073293},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.0958},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.114903},{"month":6,"riseRate":1,"avgChangeRate":0.56391},{"month":7,"riseRate":0.666667,"avgChangeRate":0.096061},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.16799},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.047954},{"month":10,"riseRate":0,"avgChangeRate":-0.160548},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.067192},{"month":12,"riseRate":0,"avgChangeRate":-0.185859}],"exchange":"NASDAQ","name":"Scienture Holdings, Inc.","nameEN":"Scienture Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Scienture Holdings, Inc.(SCNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Scienture Holdings, Inc.(SCNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Scienture Holdings, Inc.,SCNX,Scienture Holdings, Inc.股票,Scienture Holdings, Inc.股票老虎,Scienture Holdings, Inc.股票老虎国际,Scienture Holdings, Inc.行情,Scienture Holdings, Inc.股票行情,Scienture Holdings, Inc.股价,Scienture Holdings, Inc.股市,Scienture Holdings, Inc.股票价格,Scienture Holdings, Inc.股票交易,Scienture Holdings, Inc.股票购买,Scienture Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Scienture Holdings, Inc.(SCNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Scienture Holdings, Inc.(SCNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}